Cytokinetics market cap CYTK

Share price times shares outstanding: what the whole company sells for, since 2011.

Cytokinetics is worth $8.5B at the close on Oct 23, 2026, at $61.23 a share.

That is up 23% over the last year and up 192% over five years.

Its highest close in our data was $10.8B in Jul 2026.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$8.5B	$7.4B	$10.8B	+10%
2025	$7.7B	$3.6B	$8.3B	+38%
2024	$5.6B	$5.1B	$9.2B	−32%
2023	$8.2B	$2.8B	$8.2B	+89%
2022	$4.3B	$2.5B	$5.1B	+13%
2021	$3.8B	$1.3B	$3.8B	+160%
2020	$1.5B	$567.8M	$1.7B	+142%
2019	$608M	$343.1M	$826.8M	+82%
2018	$334.8M	$329.9M	$538.1M	−24%
2017	$439.2M	$409.5M	$831.8M	−11%
2016	$492.3M	$245.9M	$504.4M	+21%
2015	$406.3M	$218.5M	$466.9M	+81%
2014	$224.8M	$112.4M	$364.4M	+14%
2013	$197.4M	$113.9M	$342.3M	+110%
2012	$94M	$46.5M	$114.8M	+35%
2011	$69.4M	$69.4M	$96.9M	n/a

Companies in Drug Manufacturers - General nearest Cytokinetics' size, closest first, today.

Company	Market cap
CYTKCytokinetics	$8.5B
TGTXTG Therapeutics	$8.3B
PTGXProtagonist Therapeutics	$9B
CORTCorcept Therapeutics	$9.3B
ALKSAlkermes plc.	$7.3B
BMRNBiomarin Pharmaceutical	$10.8B
AMRXAmneal Pharmaceuticals	$6.5B
LGNDLigand Pharmaceuticals	$6.1B
KNSAKiniksa Pharmaceuticals International	$6B
JAZZJazz Pharmaceuticals	$13.9B
INDVIndivior Pharmaceuticals	$4.1B
Peer median	$7.8B